Navitoclax (ABT-263)

目录号：S1001

Navitoclax (ABT-263) Chemical Structure

Molecular Weight(MW): 974.61

Navitoclax (ABT-263)是一种有效的Bcl-xL，Bcl-2和Bcl-w抑制剂，无细胞试验中Ki分别为≤0.5 nM，≤1 nM和≤1 nM，但与Mcl-1和A1结合微弱。Phase 2。

规格 价格 库存 购买数量  
RMB 3285.53 现货
RMB 975.71 现货
RMB 1631.61 现货
RMB 3016.58 现货
RMB 7950.36 现货
有超大折扣
大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户使用Selleck该产品发表文献43篇：

客户使用该产品的13个实验数据：

  • KP cells (A) and A549 cells (B) were treated with increasing doses of ATN-224 alone or with the BCL2 inhibitor ABT-263, and cell death (96 hours) was determined.

    J Clin Invest, 2014, 124(1): 117-28 . Navitoclax (ABT-263) purchased from Selleck.

    Cell lines are also resistant to dual inhibition of Bcl-xL and Bcl-2 by the inhibitor ABT-263 when dosed with NSC siRNA, but co-dosing ABT-263 with Mcl-1 siRNA decreases compound IC50 similar to that observed with WEHI-539. Representative curves for MDA-MB-157 are shown in f.

    Cell Death Differ, 2015, 10.1038/cdd.2015.73. Navitoclax (ABT-263) purchased from Selleck.

  • ABT-263 has a higher albumin binding affinity than ABT-737. The binding capacity of ABT-737 (solid lines) and ABT-263 (dotted lines) to HSA was investigated using a fluorescence polarization assay. A, to measure binding to site 2 on HSA-IIIA, dansyl sarcosine was used as a probe. In this assay the IC50 was 711 and 37μmol/L for ABT-737 and ABT-263, respectively. B, to measure binding to site 1 on HSA-IIA, dansyl L-glutamate was used as a probe. The IC50 was >1,000 and 145 μmol/L for ABT-737 and ABT-263, respectively.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2011 408(2), 344-9. Navitoclax (ABT-263) purchased from Selleck.

     

    (A) In vitro generated  Mcl-1-deleted  Arf-/- p185+ cells stably expressing the indicated constructs were treated with indicated doses of navitoclax (ABT-263) for 24 hours after which percent viable cells were determined (propidium iodide negative cells were scored as viable). Each point represents the average of three independent experiments and the error bars denote the SEM.  p185+ Arf-/- cells serve as a control.  (B) Arf -null p185+ cells were treated with navitoclax for 24 hours at indicated doses. Lysates were immunoprecipitated with anti-BIM antibody and immune complexes were resolved and western blotted for MCL-1, BCL-2 (human specific antibody), BCL-XL, BIM, PARP and Actin (loading control). Endogenous BIM serves as the control for equal immunoprecipitation. (E&F) p185+ Arf-/- cells were treated with indicated doses of navitoclax and/or  (E) IM or  (F) DAS for 24 hours after which percent viable cells was determined. Annexin-V and PI negative cells were scored as viable. IL-7 was added to a final concentration of 20 ng/mL.

    Navitoclax (ABT-263) purchased from Selleck.

  •  

    Human Ph+ cell lines:  (A)  OP-1 Ph+ B-ALL  (B) TOM1 Ph+ B-ALL and (C)  BV173 Ph+CML blast crisis cell lines were treated with navitoclax, imatinib (IM) or dasatinib (DAS) at indicated doses for 24 hours after which cell lysates were analyzed for expression of MCL-1, BCL-2, BCL-w, BFL-1 and BCL-XL.  For potentiation experiments, the percentage of viable cells was determined by Annexin-V and PI negativity.

    Navitoclax (ABT-263) purchased from Selleck.

产品安全说明书

Bcl-2抑制剂选择性比较

生物活性

产品描述 Navitoclax (ABT-263)是一种有效的Bcl-xL，Bcl-2和Bcl-w抑制剂，无细胞试验中Ki分别为≤0.5 nM，≤1 nM和≤1 nM，但与Mcl-1和A1结合微弱。Phase 2。
靶点
Bcl-xL [1]
(Cell-free assay)		 Bcl-2 [1]
(Cell-free assay)		 Bcl-w [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki)
体外研究

ABT-263有效抑制Bcl-2蛋白家族，用荧光偏振分析法测试ABT-263作用于Bcl-xL, Bcl-2和 Bcl-w时，Ki分别为0.5, 1和1 nM。[1]ABT-263结构上与ABT-737相关。ABT-263阻断Bcl-2 和Bcl-XL与凋亡前体蛋白相互作用。Bcl-2家族成员Bcl-2,Bcl-XL, 和Mcl-1的过量表达通常都与肿瘤的修复及抗药性有关。ABT-263作用于过量表达的Bcl-2 和Bcl-XL时显示出保护作用，EC50分别为60 和20 nM。ABT-263作用于不同的细胞显示出不同的细胞活性，作用于H146细胞系时EC50为110nM,而作用于H82细胞系时EC50为22 µM。ABT-737可以有效作用于四种EC50值 <400 nM的细胞系，即H146, H889, H1963, 和H1417。而两种抗ABT-737的细胞系，即H1048和H82，同样也显示出抗ABT-263的特性。[2]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell Mm\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHoW4FKSzVyPUCuNFA3PjlizszN M1m3cnNCVkeHUh?=
MV-4-11 M4HRTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\NTWM2OD1yLkCxOVg3KM7:TR?= NWjE[mx7W0GQR1XS
NKM-1 MkTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTBwMEG2PVkh|ryP NUPMOXBnW0GQR1XS
ML-2 M17vW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rMcmlEPTB;MD6wNVk5OyEQvF2= MmK4V2FPT0WU
BV-173 MlPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTBwMEKzNVQh|ryP NFu5RYNUSU6JRWK=
RS4-11 NG\s[oRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwMEK1PFch|ryP NHjqeIJUSU6JRWK=
HL-60 NXHmc453T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH[0fFFKSzVyPUCuNFI6ODhizszN M3nieHNCVkeHUh?=
KY821 M1n6cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPzT3hKSzVyPUCuNFI6PzVizszN NVH6e5M3W0GQR1XS
ECC10 NU\INnp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\zOGlEPTB;MD6wN|c6OiEQvF2= NFzQXVNUSU6JRWK=
NCI-H720 NFflXXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWe5c4ViUUN3ME2wMlA1ODFzIN88US=> NV7TR2E6W0GQR1XS
QIMR-WIL Mk\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMESyPFch|ryP MXnTRW5ITVJ?
KG-1 MoTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHi[ZdKSzVyPUCuNFQ1QDZizszN NV7Oc|E6W0GQR1XS
TGW MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLKW5FRUUN3ME2wMlA1PjN|IN88US=> NISxOGhUSU6JRWK=
ATN-1 NV76WVRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[xdGlEPTB;MD6wOFc{OyEQvF2= MWnTRW5ITVJ?
RH-18 NVnqcIcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rRbGlEPTB;MD6wOlA1QCEQvF2= MV\TRW5ITVJ?
EW-18 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLyTWM2OD1yLkC2PFQyKM7:TR?= MWLTRW5ITVJ?
NB17 M1\DXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvhTWM2OD1yLkC3NVI1KM7:TR?= M{\tTHNCVkeHUh?=
SK-NEP-1 M1TDWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwMEeyNVMh|ryP NGfGSoZUSU6JRWK=
P12-ICHIKAWA MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\wNmlEPTB;MD6wO|c4QCEQvF2= MmjSV2FPT0WU
KARPAS-45 M{HZR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlztTWM2OD1yLkC3PFE2KM7:TR?= MoTIV2FPT0WU
EW-3 M4\UW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;mNWNKSzVyPUCuNFgxPTNizszN M17YfnNCVkeHUh?=
NB13 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4qxdWlEPTB;MD6wPFIxOyEQvF2= MVvTRW5ITVJ?
NCI-H209 NILQUmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPXTWM2OD1yLkC4O|A1KM7:TR?= M3P6eHNCVkeHUh?=
NCI-H1092 MlTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTBwMUCyO|Uh|ryP Ml3QV2FPT0WU
NH-12 MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1S5bGlEPTB;MD6xNFc1PCEQvF2= MWXTRW5ITVJ?
697 NHjBO2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPUTWM2OD1yLkGwPFM6KM7:TR?= NUHMNIJ3W0GQR1XS
KE-37 MmT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwMUGzO{DPxE1? M1zzc3NCVkeHUh?=
MOLT-4 M{XhW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXVTWM2OD1yLkG1NVY6KM7:TR?= NX\yZ3pVW0GQR1XS
CHP-134 NVzFSJJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\XVGlEPTB;MD6xOlMxPiEQvF2= NGfBSpBUSU6JRWK=
D-283MED M4\1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwMUe2PFYh|ryP NIfUd4VUSU6JRWK=
LU-135 MoLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTBwMUi1OVIh|ryP NHfrcpBUSU6JRWK=
LU-134-A NGK4V3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrCOFFzUUN3ME2wMlE5PjdzIN88US=> NVS1PIt7W0GQR1XS
EM-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvnTWM2OD1yLkG5PVE5KM7:TR?= NW\tPWNkW0GQR1XS
LU-139 M1T2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXqe|hFUUN3ME2wMlIxPDl6IN88US=> MlfvV2FPT0WU
ALL-PO Mn;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPrNotKSzVyPUCuNlE6QDhizszN NV[4S49XW0GQR1XS
NB12 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2q1SWlEPTB;MD6yN|EyPSEQvF2= MYPTRW5ITVJ?
KP-N-YN MnrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;ZNmlEPTB;MD6yN|U4OyEQvF2= MVXTRW5ITVJ?
BEN M3P4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYG0dHBVUUN3ME2wMlI{QTZ6IN88US=> NVfNRXR5W0GQR1XS
HCC1569 Mom5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUS3ZoJ2UUN3ME2wMlI2OTB4IN88US=> NIXkOWVUSU6JRWK=
HuO9 M1\sUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nrdGlEPTB;MD6yOlcyPSEQvF2= NHeySIVUSU6JRWK=
WM-115 MoLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHHWXhpUUN3ME2wMlI4PzN6IN88US=> NVvpcXBQW0GQR1XS
CCRF-CEM MmfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwM{O1Nlkh|ryP NIK4PI1USU6JRWK=
IST-SL1 MnfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PJOWlEPTB;MD6zOVM1OyEQvF2= M2r1OnNCVkeHUh?=
BE-13 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkH6TWM2OD1yLkO2OFU6KM7:TR?= MWnTRW5ITVJ?
COR-L88 M3[5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zmd2lEPTB;MD6zOlU1KM7:TR?= M3OxRnNCVkeHUh?=
DOHH-2 M4jKbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzDTWM2OD1yLkSxNFI{KM7:TR?= MlvMV2FPT0WU
A704 NYDSOmxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwNEK2O{DPxE1? MXTTRW5ITVJ?
KNS-81-FD M1ruZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnsb4FYUUN3ME2wMlQ1ODF5IN88US=> NV;4eGF6W0GQR1XS
RPMI-8226 NFz6WIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwNEW2OVIh|ryP NEDZeZpUSU6JRWK=
TGBC24TKB NH32eWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIOxd4JKSzVyPUCuOFU4PzhizszN NVfsV4RtW0GQR1XS
NCI-H1304 M1zaVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIm2emdKSzVyPUCuOFYyPTdizszN MmDnV2FPT0WU
MOLT-13 NUjzW2x5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfMTWM2OD1yLkS2OlE{KM7:TR?= M1O2T3NCVkeHUh?=
EW-22 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DWcGlEPTB;MD60OlY4OSEQvF2= NUTIUWhtW0GQR1XS
MS-1 M{K2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fRRWlEPTB;MD60Olk{OyEQvF2= NWDySGhQW0GQR1XS
RMG-I NXzNOFY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PmXGlEPTB;MD60PVQ3PCEQvF2= M4\5PXNCVkeHUh?=
NTERA-S-cl-D1 NVO2ZXAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnGTWM2OD1yLkWwNFE6KM7:TR?= NGK1OpNUSU6JRWK=
NCI-H1048 MkixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4r4WmlEPTB;MD61NFk2OyEQvF2= M4PRenNCVkeHUh?=
SW1417 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjqPFVqUUN3ME2wMlU2PDN6IN88US=> MWXTRW5ITVJ?
DB NYjiO5JlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlK2TWM2OD1yLkW3NFgh|ryP NUfo[XdTW0GQR1XS
MEG-01 NH7uWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXqxe2RkUUN3ME2wMlU5OzJizszN M3H5fXNCVkeHUh?=
EW-13 NXLuSW9IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwNUizOFEh|ryP M4nrRXNCVkeHUh?=
LAMA-84 MnWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Dmd2lEPTB;MD61PVIxPyEQvF2= M3jYUXNCVkeHUh?=
J-RT3-T3-5 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlmwTWM2OD1yLk[wPFA5KM7:TR?= NH3sc5VUSU6JRWK=
MOLT-16 M1L6V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLze5V[UUN3ME2wMlY2OjZ2IN88US=> NHzSOItUSU6JRWK=
DU-4475 Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\3XGlEPTB;MD62OVQzPyEQvF2= MYLTRW5ITVJ?
HAL-01 NW\LemU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGq2Xo5KSzVyPUCuO|I2PDlizszN NEfTcZpUSU6JRWK=
RD NVP0XIxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV74Z41QUUN3ME2wMlc2QDl7IN88US=> MYfTRW5ITVJ?
OAW-28 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzRPINKSzVyPUCuO|g{PyEQvF2= M{DXWHNCVkeHUh?=
HCC38 Ml;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYH2W5VUUUN3ME2wMlgxOTlizszN NYi5S3hGW0GQR1XS
NMC-G1 M4jUfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUX1R2txUUN3ME2wMlgyOTJzIN88US=> M{LIeXNCVkeHUh?=
EW-16 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\KOI9qUUN3ME2wMlgyOzJ6IN88US=> MXnTRW5ITVJ?
DU-145 MoLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HQW2lEPTB;MD64PVkzOyEQvF2= M2nvbHNCVkeHUh?=
HPAF-II M37s[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnu4TWM2OD1yLkmyOlI5KM7:TR?= MnrVV2FPT0WU
A427 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\4[oRWUUN3ME2wMlk{ODJ{IN88US=> M4\6UXNCVkeHUh?=
PA-1 NWPxOWZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwOUW2OFIh|ryP MULTRW5ITVJ?
OAW-42 NFTVcFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mne1TWM2OD1yLkm2NVQ3KM7:TR?= M1vxU3NCVkeHUh?=
L-428 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfzR|JKSzVyPUGuNFEzPSEQvF2= NELscGFUSU6JRWK=
COLO-824 M{C0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3ITWM2OD1zLkCxO|A5KM7:TR?= NWr0VFNnW0GQR1XS
P30-OHK MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rCOmlEPTB;MT6wOFY5QCEQvF2= MmfoV2FPT0WU
NCI-H2170 NYHtNFE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1u2cWlEPTB;MT6wOlI{KM7:TR?= MnPzV2FPT0WU
HCC2998 MmHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTFwMEexN|Uh|ryP NF:0XoJUSU6JRWK=
NB14 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTFwMUO3OFgh|ryP NV7jd|RZW0GQR1XS
TGBC1TKB MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTFwMUSxOVIh|ryP NITJTJNUSU6JRWK=
KP-N-YS NY[5dGo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XQRmlEPTB;MT6xOlI{PiEQvF2= M2jwcXNCVkeHUh?=
CAL-120 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljwTWM2OD1zLkG2OFI6KM7:TR?= M4rBfXNCVkeHUh?=
SBC-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLOcI9KSzVyPUGuNVkxPTNizszN MXLTRW5ITVJ?
C32 M1vDU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjHXYdKSzVyPUGuNVkxQDhizszN NVPtOo1SW0GQR1XS
HCC2157 NFvMc5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HP[GlEPTB;MT6xPVQ6PCEQvF2= M{PEbnNCVkeHUh?=
COLO-792 NVLXXGxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrkTWM2OD1zLkKwNFcyKM7:TR?= NEfrcZRUSU6JRWK=
ES7 M{fqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHK4Z4RKSzVyPUGuNlc6PTFizszN MWPTRW5ITVJ?
HEL MnS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1i5SWlEPTB;MT6zNVAzQSEQvF2= MYPTRW5ITVJ?
ES4 NUXQRm9pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFywSFhKSzVyPUGuN|Q6QThizszN MmXIV2FPT0WU
NCI-SNU-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIH5SFBKSzVyPUGuN|Y2PTVizszN NInvO3RUSU6JRWK=
MDA-MB-415 NXKwN45WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTFwM{i4OUDPxE1? MWHTRW5ITVJ?
NCI-H2342 MnS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\iSmlEPTB;MT60NFI3QSEQvF2= MkKyV2FPT0WU
NB69 MlrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nN[mlEPTB;MT60OlI4OSEQvF2= M3jiZXNCVkeHUh?=
D-247MG NH\CTFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHFTWM2OD1zLkWxNVIzKM7:TR?= M3mxVnNCVkeHUh?=
SCC-4 MmDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUn6WFZvUUN3ME2xMlU6QDh5IN88US=> MmfVV2FPT0WU
HuH-7 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzaTWM2OD1zLk[3Nlk{KM7:TR?= M1XvOnNCVkeHUh?=
A388 NXviRplFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPKTWM2OD1zLk[4O|I1KM7:TR?= NIjEV4hUSU6JRWK=
Calu-3 NGLiOHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4OxbmlEPTB;MT63NFY6PyEQvF2= NXWxW|hsW0GQR1XS
NCI-H1648 MnzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7aTWM2OD1zLkexOFE5KM7:TR?= NXL5TW9TW0GQR1XS
NCI-H2052 NXTndWMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTFwN{KyNFEh|ryP NYHM[oxNW0GQR1XS
Ramos-2G6-4C10 M1SwNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjB[ZZKSzVyPUGuO|M3PTZizszN Ml3nV2FPT0WU
DEL M4HkeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnwTWM2OD1zLke0OlkzKM7:TR?= M2PwUnNCVkeHUh?=
SNU-423 M4PFdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorSTWM2OD1zLke4NVU4KM7:TR?= NXHqco1pW0GQR1XS
COR-L23 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTFwN{m4O|Qh|ryP MXLTRW5ITVJ?
OMC-1 NWXsdXpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4X2dmlEPTB;MT64OlAyPiEQvF2= NX7CV4RGW0GQR1XS
EW-11 MnzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTFwOUW2OVch|ryP M2LzdnNCVkeHUh?=
HSC-3 NGTiZ4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTFwOU[zOlUh|ryP MmXIV2FPT0WU
MLMA MoHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIK3XHVKSzVyPUGuPVY3PzdizszN NVjYNVhHW0GQR1XS
RCM-1 MmrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3H6fmlEPTB;Mj6wNFM6QSEQvF2= Ml[2V2FPT0WU
MFE-280 M2\De2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTJwMEK4OFgh|ryP M{XPdXNCVkeHUh?=
ES8 NWPNT3JPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fhNmlEPTB;Mj6yOVQ4OSEQvF2= NHv2O2RUSU6JRWK=
TE-11 NV\mTZo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTJwMkm0O|Mh|ryP MWTTRW5ITVJ?
HuO-3N1 NYLDelh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkKzTWM2OD1{LkS4O|gh|ryP MmXTV2FPT0WU
MHH-NB-11 NH\5[GZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnvSWtKSzVyPUKuOVEyPThizszN NWjsSpVwW0GQR1XS
TGBC11TKB NWrySXluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWGzVmZLUUN3ME2yMlU4PjhzIN88US=> NFj5OmtUSU6JRWK=
HOP-92 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[3eGdKSzVyPUKuOVg4PDNizszN MXfTRW5ITVJ?
IGR-1 M{XQVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[yUnJJUUN3ME2yMlYzODN3IN88US=> M2G4U3NCVkeHUh?=
GOTO M4W3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XSNmlEPTB;Mj62OVM4PyEQvF2= MlTtV2FPT0WU
NCI-H1650 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJwN{KyNVUh|ryP NYrPd3pHW0GQR1XS
NCI-H1581 NIrEPYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnGR41tUUN3ME2yMlc6PjhzIN88US=> NEHC[JlUSU6JRWK=
NCI-H2405 MoLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTQZ2hZUUN3ME2yMlgzPzh{IN88US=> NELqblJUSU6JRWK=
U-118-MG MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3mSmJKSzVyPUKuPVY1QTFizszN MWTTRW5ITVJ?
DoTc2-4510 NIr6W5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHkTHR6UUN3ME2zMlAyPDF5IN88US=> NEXCdHNUSU6JRWK=
NCI-H596 M3:0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjpTYh6UUN3ME2zMlA1QTl5IN88US=> NGj2bVhUSU6JRWK=
MPP-89 NILlZZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfoTWM2OD1|LkC1OlY3KM7:TR?= NWniZnZXW0GQR1XS
GCIY MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnxXndKSzVyPUOuNlA1QTFizszN NVrrO45YW0GQR1XS
SW626 NGrBWnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2C3VmlEPTB;Mz6yOFU1OyEQvF2= MoPUV2FPT0WU
OCI-AML2 NXr0fYlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXqxPVltUUN3ME2zMlMyOjd{IN88US=> NFLtd5NUSU6JRWK=
NBsusSR NVLDOZM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXBRXVKSzVyPUOuN|Q6OzhizszN NUHRdG41W0GQR1XS
AN3-CA M4HXbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTNwNESyN|gh|ryP MXnTRW5ITVJ?
EFM-19 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{flXmlEPTB;Mz60PFM{QSEQvF2= MojOV2FPT0WU
RVH-421 NEPGVVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHqTWM2OD1|LkW2PFc4KM7:TR?= NX\lc5F4W0GQR1XS
5637 NX\LZWhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\j[5JKSzVyPUOuOlEyODNizszN MnP5V2FPT0WU
PANC-08-13 NF3RVmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHK0XWZKSzVyPUOuOlM1PzJizszN NYH3SHVWW0GQR1XS
H9 NYrO[VVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvpTWM2OD1|Lk[3NVQ1KM7:TR?= NFLHcItUSU6JRWK=
KARPAS-299 M33vNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\HTW5KSzVyPUOuOlc{PjFizszN M1nReHNCVkeHUh?=
TE-5 M{TyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTNwN{C3NFkh|ryP MmT5V2FPT0WU
NOS-1 Ml\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LhPWlEPTB;Mz63PVg{PCEQvF2= NXK0WG1JW0GQR1XS
HH M1j0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmC4TWM2OD1|LkizPFY5KM7:TR?= MXLTRW5ITVJ?
769-P NE\PPIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIq3XXRKSzVyPUOuPFk2OSEQvF2= NY\oeWE6W0GQR1XS
CHP-212 NU\UO2g3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3i4SWlEPTB;Mz65NlU1QSEQvF2= NIG0VZBUSU6JRWK=
NCI-H82 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TCPWlEPTB;Mz65OVk{PiEQvF2= NIf1dIxUSU6JRWK=
Mo-T MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjJOFZKSzVyPUSuNFQ{OTJizszN NU\WdHhzW0GQR1XS
BB65-RCC NWLG[nBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\OTWM2OD12LkC0N|k6KM7:TR?= NGixc3hUSU6JRWK=
SW1990 NEXGdoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTRwMEW5NFgh|ryP MWrTRW5ITVJ?
LK-2 NX3GfXFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPoTWM2OD12LkGxNlk{KM7:TR?= MWTTRW5ITVJ?
ES5 M2e4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTSTWM2OD12LkGzPVg2KM7:TR?= MofOV2FPT0WU
JVM-3 M2nRbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDjd5RYUUN3ME20MlE5OjJ{IN88US=> NV25R3hlW0GQR1XS
RPMI-7951 NIrRPZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWmx[2FDUUN3ME20MlIzPDF|IN88US=> NVTLSItyW0GQR1XS
Calu-6 Ml7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTRwMke4PFEh|ryP NGjScY5USU6JRWK=
LC-2-ad M4Xxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2C4XWlEPTB;ND6yPVU3QCEQvF2= NVi2SWxGW0GQR1XS
SW954 M4PieGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rjV2lEPTB;ND6yPVY3KM7:TR?= MVTTRW5ITVJ?
H-EMC-SS MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\1NGlEPTB;ND6zNVg{OSEQvF2= NFLLR5JUSU6JRWK=
ES3 MkL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;KNYdoUUN3ME20MlM2PDRzIN88US=> NGXnXJRUSU6JRWK=
no-11 M3HoNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3oclF6UUN3ME20MlM2PTV2IN88US=> MVHTRW5ITVJ?
LAN-6 MmewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvyTWM2OD12LkS1NVg6KM7:TR?= NYW3WVlFW0GQR1XS
FTC-133 MnXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTRwNUO5OUDPxE1? MUDTRW5ITVJ?
8505C NIWzfJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljNTWM2OD12LkW0NlMh|ryP NI\TeY5USU6JRWK=
SW620 NGXUN4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vufWlEPTB;ND61O|A2PyEQvF2= NYHiO25UW0GQR1XS
BCPAP NY[yeGc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\xd5R4UUN3ME20MlY{PDhzIN88US=> M{PKeXNCVkeHUh?=
SK-LU-1 M1G3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYn2OGpoUUN3ME20MlY3ODh7IN88US=> M4L6V3NCVkeHUh?=
NCI-H1623 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETFS2pKSzVyPUSuO|AzOjhizszN NHLrVoRUSU6JRWK=
C2BBe1 M{fLe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;LUYdGUUN3ME20Mlc1ODB6IN88US=> NFnUdGZUSU6JRWK=
GP5d MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnERnppUUN3ME20Mlc5Ozh6IN88US=> NXyzVJZTW0GQR1XS
NB6 MmPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP6TWM2OD12Lki2NlA1KM7:TR?= MmnnV2FPT0WU
MDA-MB-157 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfUW4lKSzVyPUSuPFg4PiEQvF2= NEHLbZZUSU6JRWK=
UMC-11 M4HHSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTRwOEi5OlQh|ryP NXjqZnd5W0GQR1XS
HCC1419 NEPUXVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4K0O2lEPTB;ND65NFA3OyEQvF2= MVnTRW5ITVJ?
NCI-H2029 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIW4dI1KSzVyPUSuPVQyQDVizszN NF\RTm5USU6JRWK=
LXF-289 NILYbm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7QTWM2OD13LkCzO|E6KM7:TR?= M1;wXnNCVkeHUh?=
KINGS-1 NYn5N5NmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTVwMEe3OFQh|ryP NGPXO3BUSU6JRWK=
HD-MY-Z NIL3bHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3n3NmlEPTB;NT6yN|k3QSEQvF2= NYm4N483W0GQR1XS
ESS-1 MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml21TWM2OD13LkK1OVk4KM7:TR?= M3i0Z3NCVkeHUh?=
GI-1 NE\LUpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTrRVcyUUN3ME21MlI4QTJ4IN88US=> Ml\UV2FPT0WU
RPMI-2650 M3\pc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXvSY9KSzVyPUWuN|YyPiEQvF2= MWLTRW5ITVJ?
IA-LM NU\4N5drT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYr6bFdJUUN3ME21MlM6QDdzIN88US=> NXTMdXcyW0GQR1XS
KP-4 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXNTWM2OD13LkS2N|M1KM7:TR?= NHvneZFUSU6JRWK=
G-402 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTVwNUG4OlUh|ryP MX7TRW5ITVJ?
OS-RC-2 NHnlV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfWUZhpUUN3ME21MlUzPjB2IN88US=> NHvuWZVUSU6JRWK=
NCI-H1155 NFTieIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjsOJBKUUN3ME21MlU1QTV3IN88US=> M1G0cnNCVkeHUh?=
OE19 M3\OV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XES2lEPTB;NT62PFYzPCEQvF2= NGCyXppUSU6JRWK=
U-2-OS MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYqzcpdEUUN3ME21Mlg6ODF|IN88US=> NH;nS5ZUSU6JRWK=
SCC-15 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTVwOUO2OlIh|ryP NI\yfZVUSU6JRWK=
NCI-H630 M1rqWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPmUpBKSzVyPUWuPVk1ODRizszN NUTBWZJbW0GQR1XS
PFSK-1 M4rqR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DzdGlEPTB;Nj6wOVI2QSEQvF2= MVjTRW5ITVJ?
NCI-H1770 NYXFdIJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkT0TWM2OD14LkKwPFc1KM7:TR?= NInLZoJUSU6JRWK=
SK-MEL-3 M2T1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVqzXW9GUUN3ME22MlQzQTF3IN88US=> MWjTRW5ITVJ?
LB1047-RCC M33ZbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYq0OIoxUUN3ME22MlQ4PjJ3IN88US=> NX;YO45jW0GQR1XS
NCI-H446 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnjNo5nUUN3ME22MlYzQTJ3IN88US=> NWLaSWljW0GQR1XS
SW780 NUmxVWhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTZwN{CxPFUh|ryP MV7TRW5ITVJ?
NEC8 NWjmR|VKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnG2TWM2OD14Lke2OlMh|ryP NVPJWZpjW0GQR1XS
NOMO-1 NFn6RZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLnTWM2OD14Lke4NVEyKM7:TR?= MYLTRW5ITVJ?
COLO-668 MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DHW2lEPTB;Nj64OFM5PyEQvF2= NFvQPZZUSU6JRWK=
MC116 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvXfnNKSzVyPU[uPVM5QTdizszN NYrPUGlRW0GQR1XS
HCC1937 NXTKdm95T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33tXWlEPTB;Nj65PVI2OSEQvF2= M1HNTHNCVkeHUh?=
NCI-N87 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPZTWM2OD15LkG5Nlk{KM7:TR?= M1eyWnNCVkeHUh?=
COLO-320-HSR MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrxcJFKSzVyPUeuNlI4OzhizszN MoL0V2FPT0WU
HCC1806 Mne1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDIS4xKSzVyPUeuNlYxPDRizszN MnfZV2FPT0WU
OVCAR-3 Mn3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3VVWlyUUN3ME23MlM{ODN6IN88US=> MkjIV2FPT0WU
NUGC-3 M4jrUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTdwM{m2PVQh|ryP NIjqeYlUSU6JRWK=
SW1783 M2[xW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLyTWM2OD15LkSzNVc2KM7:TR?= MmTPV2FPT0WU
GCT MlnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTdwNU[5NFYh|ryP MW\TRW5ITVJ?
NCI-H2126 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTdwN{O2NlUh|ryP NUPuWFlmW0GQR1XS
MEL-HO M13Jdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlT1TWM2OD15Lke3NFU1KM7:TR?= MmrQV2FPT0WU
CAPAN-1 M{TjfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTdwN{ezOVch|ryP NEH3cIVUSU6JRWK=
SW756 Moe4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojrTWM2OD15Lke4N|M{KM7:TR?= M2q5V3NCVkeHUh?=
SKG-IIIa MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvPTWM2OD15LkixPFkzKM7:TR?= MnrsV2FPT0WU
HCE-T MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXKxT4pHUUN3ME23Mlg4Pzh|IN88US=> NXnmTYhZW0GQR1XS
Ca-Ski MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;jVWtPUUN3ME23Mlk6Ozh|IN88US=> NUHvfppEW0GQR1XS
COLO-684 M4LuPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvPTZJKSzVyPUiuNFE5OThizszN NEPSd2FUSU6JRWK=
KYSE-70 NWKwS4hET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfsTWM2OD16LkC3O|I6KM7:TR?= MYHTRW5ITVJ?
TI-73 NHzoWW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHjTWM2OD16LkK1PFUyKM7:TR?= MYrTRW5ITVJ?
BT-20 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXK1N|NoUUN3ME24MlI3ODV{IN88US=> M2TlTnNCVkeHUh?=
MHH-ES-1 Mo[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjYUGlEUUN3ME24MlUyQDN2IN88US=> MUjTRW5ITVJ?
TE-12 NWHzepE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{H1TmlEPTB;OD61PVk{OSEQvF2= M2XNWHNCVkeHUh?=
YH-13 MnP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3W2S2lEPTB;OD62NVAxQCEQvF2= NWjx[IpWW0GQR1XS
SF126 NV3aUmlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXmTWM2OD16LkizPFY2KM7:TR?= M{fkN3NCVkeHUh?=
J82 MnTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRThwOUCwN|gh|ryP MYLTRW5ITVJ?
RCC10RGB NIWyRYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;HTWM2OD16Lkm5OVYyKM7:TR?= M{DBOHNCVkeHUh?=
SK-UT-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnuxTWM2OD17LkC0PVQ2KM7:TR?= NGPDeFJUSU6JRWK=
LB2241-RCC NHvteJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTlwMUmxN|ch|ryP NGPoc5FUSU6JRWK=
LB996-RCC MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTGTWM2OD17LkG5PFkh|ryP MonIV2FPT0WU
EPLC-272H MlfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTlwM{e2OVch|ryP NYLFUWxpW0GQR1XS
CTV-1 NGq3PGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWWzW3VMUUN3ME25MlU3PTN{IN88US=> NFTBOllUSU6JRWK=
HSC-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\1[m92UUN3ME25MlU4PTVizszN NYLUdFRsW0GQR1XS
SK-MEL-28 Mn7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTlwNkG4PVMh|ryP MX\TRW5ITVJ?
MMAC-SF M4PUcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fVTGlEPTB;OT62PFc2KM7:TR?= NVPpcZd{W0GQR1XS
CP50-MEL-B M336O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HibWlEPTB;OT63OVc5OiEQvF2= M2q2eHNCVkeHUh?=
HT-1080 NG\CNHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17WUmlEPTB;OT63O|c{QSEQvF2= NX6xO3BLW0GQR1XS
HEC-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFu3d2FKSzVyPUGwMlM{PTJizszN MlPFV2FPT0WU
AGS MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonrTWM2OD1zMD6zO|Qh|ryP MV7TRW5ITVJ?
GAMG NUfvWo9ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTFyLkWxOlIh|ryP MV;TRW5ITVJ?
SW48 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;uTWM2OD1zMD61NVg6KM7:TR?= MYLTRW5ITVJ?
U031 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTFyLkW5NFgh|ryP NFnBVnBUSU6JRWK=
OVCAR-5 MnPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PSS2lEPTB;MUCuOlQzQSEQvF2= NXO4SFM1W0GQR1XS
SF295 M{DsW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3ywOmlEPTB;MUCuOlcxPCEQvF2= NH7BXo5USU6JRWK=
BHT-101 M2jMSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;DTWM2OD1zMD63NVc4KM7:TR?= NYrZeVVKW0GQR1XS
VMRC-RCZ NVHicGNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTFzLkOyNFEh|ryP M3znV3NCVkeHUh?=
ACHN MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHXTWM2OD1zMT60NlEyKM7:TR?= MnzPV2FPT0WU
NCI-H526 M4\2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTFzLkWwOFMh|ryP MVzTRW5ITVJ?
MN-60 M3rUWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHS0XlNKSzVyPUGxMlU{QSEQvF2= MVTTRW5ITVJ?
NCI-H2291 NW\VR3pZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXnTWM2OD1zMT61OFY3KM7:TR?= NHvkc5RUSU6JRWK=
SCC-25 NHXVc|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUm0NohtUUN3ME2xNU44PTV4IN88US=> NUPkWI15W0GQR1XS
SK-MEL-2 NGDTVnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLCOWd7UUN3ME2xNU44PjN5IN88US=> NULFPYlUW0GQR1XS
SN12C MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HG[WlEPTB;MUGuPVM2PSEQvF2= MULTRW5ITVJ?
NCI-H69 NEjTUpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEWwSo1KSzVyPUGyMlQzOzRizszN NELidIdUSU6JRWK=
ME-180 NUGwT2ptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\3SmRKSzVyPUGyMlcxPTRizszN M{LWUXNCVkeHUh?=
MC-IXC NXrEPW5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[xTWM2OD1zMj63OVE5KM7:TR?= NG[yWoFUSU6JRWK=
NCI-H2347 M4n0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnq3TWM2OD1zMj63OlE1KM7:TR?= NFrwd5NUSU6JRWK=
M059J NF3YXlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\4TWM2OD1zMj63O|I4KM7:TR?= M{THTXNCVkeHUh?=
A2058 MnnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTF{Lki2PFEh|ryP NGfLOVRUSU6JRWK=
VA-ES-BJ MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHSzNmxKSzVyPUGyMlg4QDVizszN MnzZV2FPT0WU
Ca9-22 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTKXnhKSzVyPUGyMlk1PTFizszN NV7Tc3hCW0GQR1XS
KNS-42 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjoS4pwUUN3ME2xNk46QTh2IN88US=> MVfTRW5ITVJ?
LoVo M1\oTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PqOmlEPTB;MUOuNlMyOyEQvF2= NFHWcm9USU6JRWK=
AM-38 NWjFfppPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTF|LkK1OlYh|ryP NFqyWJBUSU6JRWK=
NB5 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzsTWM2OD1zMz6zO|UzKM7:TR?= M12weXNCVkeHUh?=
L-363 M{LSb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33FOWlEPTB;MUOuOFA{OyEQvF2= MkLKV2FPT0WU
SK-MEL-30 MlzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITOd2tKSzVyPUG0MlA3PDVizszN M2XxXHNCVkeHUh?=
NCI-H1563 NWL3WJFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MormTWM2OD1zND62NFM6KM7:TR?= MVPTRW5ITVJ?
NCI-H2228 M1PzXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HTOGlEPTB;MUSuOlA4PyEQvF2= MXHTRW5ITVJ?
MFM-223 NGLLflBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13mUWlEPTB;MUWuNVgyOyEQvF2= M2LpT3NCVkeHUh?=
LB831-BLC MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTF3LkK3Olch|ryP NHPSeHVUSU6JRWK=
SW872 M3PRVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPYTWM2OD1zNT6zNFg3KM7:TR?= Mn7RV2FPT0WU
NCI-H522 NUDUc2cyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnP2TWM2OD1zNT6zN|A3KM7:TR?= NFTFbZJUSU6JRWK=
EW-1 MlfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTF3LkW0OlIh|ryP NFvCWmhUSU6JRWK=
HN MonkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTF3LkW5OFIh|ryP NHy2cVVUSU6JRWK=
SW837 M32we2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTF3Lke4OFch|ryP MnKzV2FPT0WU
SCC-9 NIjyUFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{O4d2lEPTB;MUWuPFEyPCEQvF2= MX;TRW5ITVJ?
MKN7 NGfuPW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fWR2lEPTB;MUWuPVc{OiEQvF2= M3fu[XNCVkeHUh?=
KYSE-410 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGKwXoRKSzVyPUG2MlU6OSEQvF2= MYXTRW5ITVJ?
SK-N-DZ M37PWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjXSINYUUN3ME2xOk43OTF4IN88US=> NYfMPJhoW0GQR1XS
COR-L105 NIKwWHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P1UGlEPTB;MU[uOlUzQCEQvF2= MmfnV2FPT0WU
LB2518-MEL NWDFZVZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmr3TWM2OD1zNj64N|g6KM7:TR?= M3HHcHNCVkeHUh?=
OVCAR-4 NGPE[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvuTWM2OD1zNj64PFYzKM7:TR?= MXfTRW5ITVJ?
TK10 NV7ab2VGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmG3TWM2OD1zNj65OFc{KM7:TR?= MmLhV2FPT0WU
KNS-62 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEL2NpRKSzVyPUG2Mlk4PzdizszN MmK4V2FPT0WU
RPMI-8866 MoHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjIS2lnUUN3ME2xO{4yPzN{IN88US=> NVTT[ZY1W0GQR1XS
HuP-T4 NI\NWIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTF5LkK0PVUh|ryP M1H4UnNCVkeHUh?=
CGTH-W-1 NW\XcFY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDLTItKSzVyPUG3MlUzOTlizszN M1fUSHNCVkeHUh?=
T-24 NY\yZXcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLUTpljUUN3ME2xO{42OzR5IN88US=> MnvkV2FPT0WU
HT-3 NGrmN4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TU[WlEPTB;MUeuOVkyPCEQvF2= M1nmR3NCVkeHUh?=
KS-1 NX7seXFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjSSXZKSzVyPUG3MlY4OyEQvF2= NWn5eog{W0GQR1XS
NCI-H1792 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[wZ2lEPTB;MUeuO|k5KM7:TR?= MUjTRW5ITVJ?
ABC-1 MkfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjQTWM2OD1zNz64NVQyKM7:TR?= M33MS3NCVkeHUh?=
BPH-1 NV7pPXg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTF6LkG2PFUh|ryP MXfTRW5ITVJ?
A431 NUfvZpJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4n4fWlEPTB;MUiuOFEzPyEQvF2= M3HBPXNCVkeHUh?=
T98G NGLWNYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\tN2lEPTB;MUiuOVE2PyEQvF2= NFzJTWRUSU6JRWK=
BHY MlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTF6Lki2PUDPxE1? NIfsdXNUSU6JRWK=
Capan-2 M3\JfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XUO2lEPTB;MUiuPVA4QCEQvF2= NFXDOlRUSU6JRWK=
MDA-MB-175-VII NVfC[VVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4T2ZmlEPTB;MUiuPVIxQSEQvF2= M2fDR3NCVkeHUh?=
CAL-27 NEnIOohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGm4eZBKSzVyPUG5MlA1QDdizszN NVP1TY5GW0GQR1XS
AsPC-1 M{LzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnGxTWM2OD1zOT64OlU4KM7:TR?= NU\qOY5pW0GQR1XS
KU812 NGi5SpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofLTWM2OD1zOT65OVc{KM7:TR?= MkTtV2FPT0WU
NCI-H441 NXe4bYJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrPVIJLUUN3ME2yNE4xODFizszN Mlj4V2FPT0WU
Mewo NW\jN5VmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjkZW1KSzVyPUKwMlEzQDhizszN MUTTRW5ITVJ?
SK-MEL-24 M{fTWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXH4[m17UUN3ME2yNE4yPDd5IN88US=> M1r4VnNCVkeHUh?=
NCI-H727 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHhSIQ4UUN3ME2yNE4zPzB2IN88US=> NIDkbFNUSU6JRWK=
EKVX NHyxXZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzHXXlUUUN3ME2yNE43ODZizszN MXrTRW5ITVJ?
RT-112 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfCTWM2OD1{MD62NVIzKM7:TR?= NEHKO29USU6JRWK=
CAMA-1 NGflNo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLJTWM2OD1{MD65PFA{KM7:TR?= Mn7VV2FPT0WU
SW900 NV\JN28zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NES5Z3BKSzVyPUKxMlAyPDlizszN NGXZe2RUSU6JRWK=
NCI-H23 Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjP[W5qUUN3ME2yNU4yOjd5IN88US=> NHrHTFZUSU6JRWK=
SK-PN-DW MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofDTWM2OD1{MT6xOlQ6KM7:TR?= NFPINpJUSU6JRWK=
BB30-HNC NXyyW|NiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPFZ2N[UUN3ME2yNU4zPzR3IN88US=> Ml\xV2FPT0WU
VM-CUB-1 Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3QTVZKSzVyPUKxMlM2OzZizszN M1uwZ3NCVkeHUh?=
IST-MEL1 M{fDOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fjV2lEPTB;MkGuN|Y6OiEQvF2= MYDTRW5ITVJ?
CTB-1 NUP0OIdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXsPGRNUUN3ME2yNU41PzV3IN88US=> NYj4enZ5W0GQR1XS
LCLC-103H M{Oxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzpTmY5UUN3ME2yNk4yPTh{IN88US=> NE\1N4JUSU6JRWK=
PANC-03-27 MojsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGG4UmtKSzVyPUKyMlUyPjlizszN NWf1bYVEW0GQR1XS
HTC-C3 NFO0SYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrXTWM2OD1{Mj61OVU2KM7:TR?= MUjTRW5ITVJ?
TE-8 M1XpfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7yZphJUUN3ME2yN{4zPTZ3IN88US=> MljFV2FPT0WU
NCI-H292 M{LsSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mle1TWM2OD1{NT6zOVM3KM7:TR?= NYDWd4Z[W0GQR1XS
COLO-680N NX3LOmlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULKfVluUUN3ME2yOU43OzJ7IN88US=> M3fVXnNCVkeHUh?=
KYSE-520 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPKbm9KSzVyPUK1MlY1PCEQvF2= NYD1VlFXW0GQR1XS
NB10 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjR[nFKSzVyPUK2MlMyOTdizszN NXG0d|dIW0GQR1XS
NCI-H661 NYDlR2pHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPYTWM2OD1{Nj60O|E{KM7:TR?= MWHTRW5ITVJ?
GMS-10 NX7Ec2JIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknrTWM2OD1{Nj64OlM5KM7:TR?= MUfTRW5ITVJ?
NCI-H2122 Moi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTJ4Lkm5PVgh|ryP MWTTRW5ITVJ?
OVCAR-8 NELPTYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\PTWM2OD1{Nz6wOlM5KM7:TR?= MlzGV2FPT0WU
DJM-1 MkLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnGTWM2OD1{Nz6xOFU1KM7:TR?= MlvhV2FPT0WU
UACC-893 NUm4O4hCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XGeWlEPTB;MkeuPVg4QCEQvF2= NX3WXVN5W0GQR1XS
C8166 M2fEe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGq4fJVKSzVyPUK4MlY6OzhizszN NVfm[4J4W0GQR1XS
NCI-H1693 MlvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PPPWlEPTB;MkiuOlk4PSEQvF2= M1L4b3NCVkeHUh?=
TYK-nu NFK2NFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTNyLkCzOFUh|ryP M3TwdXNCVkeHUh?=
SW1710 M37QT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLxflU5UUN3ME2zNE4yOjZizszN MWPTRW5ITVJ?
A375 NXHTeGpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTNyLkOyOFMh|ryP MVnTRW5ITVJ?
HMV-II MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPxTm1iUUN3ME2zNU4{PTl{IN88US=> MYjTRW5ITVJ?
NCI-H2087 NFn6[pZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NImzT2ZKSzVyPUOxMlY{PTJizszN NETVSVZUSU6JRWK=
CAL-54 NH3P[|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXZNWFGUUN3ME2zNU44OjRzIN88US=> NXfmcnlMW0GQR1XS
HCC70 NH;BPXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTN{LkGzPFch|ryP NFvLbFVUSU6JRWK=
ES1 NXjUSppnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTN{LkOwOlIh|ryP MoXZV2FPT0WU
NCI-H1355 MkTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTN|LkKwOEDPxE1? MkfoV2FPT0WU
CFPAC-1 M1HufGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXkOZNRUUN3ME2zN{4zOzN{IN88US=> MoLCV2FPT0WU
MKN28 NFSydllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\JVZZQUUN3ME2zN{4{QDB7IN88US=> NF\nO4VUSU6JRWK=
HDLM-2 NEnGOWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;6TZFKSzVyPUOzMlY6OzFizszN MVTTRW5ITVJ?
PANC-10-05 M{\RT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTN2LkGwNVQh|ryP NF73ZnlUSU6JRWK=
SAS NYCzXHo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDHUZlKSzVyPUO0MlQ2PjVizszN M2ThVXNCVkeHUh?=
HCC1395 NWHEZVdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jHOWlEPTB;M{SuO|E5PiEQvF2= Mlj3V2FPT0WU
8305C NFP5NZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XTdWlEPTB;M{WuPFQyPSEQvF2= M3zvNHNCVkeHUh?=
KM12 NGPZbWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\iPGlEPTB;M{[uO|U1PyEQvF2= NULwWm1qW0GQR1XS
SW1116 MojkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTN5LkW5PVIh|ryP MYXTRW5ITVJ?
SK-MEL-1 M3j6OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XCS2lEPTB;M{iuN|M5QSEQvF2= MnvXV2FPT0WU
HCC2218 M3jzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7BcoxVUUN3ME2zPE43PTF7IN88US=> NXm0OnROW0GQR1XS
T84 MnnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoP1TWM2OD1|OD63OFA6KM7:TR?= Mnq3V2FPT0WU
ETK-1 MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPpTWM2OD1|OT6wNlIh|ryP MnPPV2FPT0WU
COLO-800 M4HPbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPkTWM2OD1|OT6zPFY5KM7:TR?= MUXTRW5ITVJ?
CAL-12T MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fGd2lEPTB;M{muOVI5OSEQvF2= M3vQZ3NCVkeHUh?=
ACN MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHDdW1KSzVyPUSwMlQ6OTFizszN MlTSV2FPT0WU
SJSA-1 MmTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfjTWM2OD12MT6xOVk3KM7:TR?= M1LXRnNCVkeHUh?=
PSN1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTRzLkG3OFkh|ryP Ml;UV2FPT0WU
D-566MG NULJW4tjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTRzLkKwPFYh|ryP NGGzc2lUSU6JRWK=
EGI-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPIdGZKSzVyPUSyMlQzQCEQvF2= MlvxV2FPT0WU
A204 M3;XfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXO3SoJqUUN3ME20Nk43Ozh6IN88US=> MUfTRW5ITVJ?
Saos-2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4m2e2lEPTB;NEKuPFM3QSEQvF2= NF\ZRZJUSU6JRWK=
SNU-C2B NGjSUm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjwTWM2OD12Mz62PFc5KM7:TR?= M1W4ZXNCVkeHUh?=
HLE Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vLNWlEPTB;NESuNFg2PiEQvF2= NXrvW4JFW0GQR1XS
SW1463 M4PLOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\4TWM2OD12ND65PVcyKM7:TR?= M2DCN3NCVkeHUh?=
DSH1 MlG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XVfGlEPTB;NEWuNFA{OyEQvF2= Ml;0V2FPT0WU
MCF7 M2K0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTR3LkWwOVEh|ryP NFPGS|FUSU6JRWK=
K5 MnzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmH5TWM2OD12NT65OFA2KM7:TR?= M4WzeHNCVkeHUh?=
NCI-H358 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYixcJJQUUN3ME20O{4zOTVizszN NVXGeFY3W0GQR1XS
NCI-H2030 NYC3bZJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTR5LkKzO|Qh|ryP Mn3UV2FPT0WU
SW948 NELxO|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTR5LkS2OEDPxE1? NGO0VllUSU6JRWK=
BALL-1 NHq2bZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYL2cWpGUUN3ME20O{43OTZ6IN88US=> NEK4N41USU6JRWK=
TE-9 NETDO3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTR5Lkm1PFEh|ryP MXLTRW5ITVJ?
SK-N-FI NEG3U2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;ufVBKSzVyPUS4MlA{PThizszN MnryV2FPT0WU
KALS-1 MmnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHi5cGpKSzVyPUS4MlEzQDlizszN MkfHV2FPT0WU
HO-1-N-1 Mom1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnBUJNtUUN3ME20PE44PDR3IN88US=> NEDRNWlUSU6JRWK=
NCI-H2452 Ml\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVP3[|FRUUN3ME20PU4yOTV{IN88US=> MXLTRW5ITVJ?
OC-314 NFTvVJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTR7Lk[4N|Qh|ryP MnToV2FPT0WU

... Click to View More Cell Line Experimental Data
体内研究 用ABT-263处理H345移植瘤模型，按动物体重，每千克每天处理10mg ABT-263，结果肿瘤生长抑制率达80% ，肿瘤体积减小了50%以上，显示出ABT-263极强的抗癌效果。ABT-263作用于非小细胞肺癌和急性淋巴细胞白血病的移植瘤模型时，每天单独口服，结果显示肿瘤完全衰退。ABT-263单独作用于B-细胞淋巴瘤和多发性骨髓瘤的移植瘤模型时效果不明显，但是可以显著增强临床其他相关用药的药性。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验：

[1]
+ 展开

激酶实验:

用竞争性荧光偏振检测测定ABT-263 作用于Bcl-2 家族不同亚型的Ki值或者IC50值。使用如下的肽探针对或者蛋白对：f-bad (1 nM) 和Bcl-xL (6 nM), f-Bax (1 nM) 和Bcl-2 (10 nM), f-Bax (1 nM) 和Bcl-w (40 nM), f-Noxa (2 nM)和Mcl-1 (40 nM), 及f-Bax (1 nM) 和Bcl-2-A1 (15 nM)。用时间分辨荧光共振能转移法测定ABT-263和Bcl-xL作用的结合紧密度。1 nM 用His标记的Bcl-xL 与200 nM f-Bak,及 1 nM Tb标记的His抗体混合, 然后在室温下处理30分钟。
细胞实验：

[1]
+ 展开
  • Cell lines: SCLC 细胞系
  • Concentrations: 0-1 μM
  • Incubation Time: 48小时
  • Method:

    人类肿瘤细胞系在37oC 含5% CO2环境下获得，SCLC 细胞系培养在RPMI 1640培养基中，培养基包含10% 胎牛血清, 1% 丙酮酸钠, 25 mM HEPES, 4.5 g/L葡萄糖, 1% 青霉素/链霉素。用含有10% FBS和1% 青霉素/链霉素的RPMI 1640培养基培养白血病和淋巴癌细胞系。细胞在96孔板上处理48小时，最终体积达到100ul。在体外测试ABT-263的细胞毒性。


    (Only for Reference)
动物实验：

[1]
+ 展开
  • Animal Models: C.B.-17严重联合免疫缺陷-米黄鼠
  • Formulation: ABT-263在10% 乙醇, 30% 聚乙二醇400, 及60% Phosal 50 PG中制成
  • Dosages: 100 mg/kg/d
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (102.6 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)：
5% DMSO+corn oil 		7mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 974.61
化学式

C47H55ClF3N5O6S3
CAS号 923564-51-6
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03366103 Recruiting Metastatic Malignant Solid Neoplasm|Recurrent Malignant Solid Neoplasm|Recurrent Small Cell Lung Carcinoma|Stage III Small Cell Lung Carcinoma AJCC v7|Stage IIIA Small Cell Lung Carcinoma AJCC v7|Stage IIIB Small Cell Lung Carcinoma AJCC v7|Stage IV Small Cell Lung Carcinoma AJCC v7|Unresectable Solid Neoplasm National Cancer Institute (NCI) November 29 2017 Phase 1|Phase 2
NCT03181126 Recruiting Acute Lymphoblastic Leukemia (ALL)|Lymphoblastic Lymphoma AbbVie November 28 2017 Phase 1
NCT03222609 Recruiting Myelofibrosis (MF) AbbVie October 31 2017 Phase 2
NCT02520778 Recruiting EGFR Activating Mutation|EGFR Exon 19 Deletion Mutation|EGFR NP_005219.2:p.G719X|EGFR NP_005219.2:p.L858R|EGFR NP_005219.2:p.L861Q|EGFR NP_005219.2:p.T790M|Stage III Non-Small Cell Lung Cancer AJCC v7|Stage IIIA Non-Small Cell Lung Cancer AJCC v7|Stage IIIB Lung Non-Small Cell Cancer AJCC v7|Stage IV Non-Small Cell Lung Cancer AJCC v7 National Cancer Institute (NCI) March 31 2016 Phase 1
NCT02591095 Active not recruiting Platinum-resistant or Refractory Ovarian Cancer Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Cancer Research Hospital Program January 2016 Phase 2
NCT02143401 Recruiting Cirrhosis|Hepatitis B Infection|Hepatitis C Infection|Metastatic Malignant Solid Neoplasm|Recurrent Hepatocellular Carcinoma|Recurrent Malignant Solid Neoplasm|Refractory Malignant Neoplasm|Stage IV Hepatocellular Carcinoma AJCC v7|Unresectable Solid Neoplasm National Cancer Institute (NCI) November 7 2014 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1：

    I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?

  • 回答：

    S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.

  • 问题 2：

    Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?

  • 回答：

    According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Selleck产品目录册

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

  • 选择性强的Bcl-2抑制剂

    ABT-199 (GDC-0199) : Bcl-2-selective, Ki<0.01 nM.

  • 用于临床的Bcl-2抑制剂

    Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.

  • 最新的Bcl-2家族激活剂

    BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.

  • 经典的Bcl-2抑制剂

    ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

相关Bcl-2产品

  • A-1210477 New

    A-1210477是一种有效的选择性MCL-1抑制剂，Ki和IC50分别为0.454 nM 和 26.2 nM，选择性比作用于其他Bcl-2家族成员高100多倍。

  • MI-773 (SAR405838) New

    MI-773 (SAR405838) 是一种口服生物有效的MDM2拮抗剂，Ki为0.88 nM。Phase 1。

  • Venetoclax (ABT-199, GDC-0199)

    Venetoclax (ABT-199, GDC-0199)是一种Bcl-2选择性抑制剂，无细胞试验中Ki为<0.01 nM，比作用于Bcl-xL和Bcl-w选择性高4800倍以上，对Mcl-1没有抑制活性。Phase 3。

    Features:ABT-263 (Navitoclax)的重组

  • ABT-737

    ABT-737是一种BH3模拟抑制剂，作用于Bcl-xL，Bcl-2和Bcl-w，无细胞试验中EC50分别为78.7 nM，30.3 nM和197.8 nM；但对Mcl-1， Bcl-B及Bfl-1没有抑制作用。Phase 2。

    Features:ABT-737是第一代抗凋亡BCL-2家族蛋白小分子抑制剂。

  • UMI-77

    UMI-77是一种选择性Mcl-1抑制剂，Ki为490 nM，表现出高于Bcl-2家族其它成员的选择性。

  • Obatoclax Mesylate (GX15-070)

    Obatoclax Mesylate (GX15-070)是一种Bcl-2拮抗剂，无细胞试验中Ki为0.22 μM，可以协助抑制MCL-1介导的抗细胞凋亡作用。Phase 3。

    Features:Obatoclax是有应用前景的小分子Bcl-2拮抗剂，抑制Bcl-2蛋白家族所有相关的膜结构，包括 Mcl-1。

  • TW-37

    TW-37是一种新型的非肽类抑制剂，作用于重组Bcl-2，Bcl-xL和Mcl-1，无细胞试验中Ki分别为0.29 μM， 1.11 μM和0.26 μM。

    Features:TW-37是新型非肽类小分子 Bcl-2抑制剂。

  • Sabutoclax

    Sabutoclax是一种pan-Bcl-2抑制剂，作用于Bcl-xL， Bcl-2， Mcl-1和Bfl-1，IC50分别为0.31 μM， 0.32 μM， 0.20 μM和0.62 μM。

  • AT101

    AT101，是醋酸棉酚的R-(-)对映体，与Bcl-2，Bcl-xL和Mcl-1结合，无细胞试验中Ki为0.32 μM，0.48 μM 和 0.18 μM；不抑制BIR3域和BID。Phase 2。

Tags: 购买Navitoclax (ABT-263) | Navitoclax (ABT-263)供应商 | 采购Navitoclax (ABT-263) | Navitoclax (ABT-263)价格 | Navitoclax (ABT-263)生产 | 订购Navitoclax (ABT-263) | Navitoclax (ABT-263)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID